KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Shares Outstanding (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Shares Outstanding for 17 consecutive years, with $162.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 45.95% to $162.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162.0 million through Dec 2025, up 45.95% year-over-year, with the annual reading at $162.0 million for FY2025, 45.95% up from the prior year.
  • Shares Outstanding hit $110.0 million in Q4 2025 for Quest Diagnostics, down from $111.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $217.0 million in Q1 2021 to a low of $110.0 million in Q4 2025.
  • Historically, Shares Outstanding has averaged $143.3 million across 5 years, with a median of $142.5 million in 2021.
  • Biggest five-year swings in Shares Outstanding: crashed 46.08% in 2022 and later skyrocketed 45.95% in 2025.
  • Year by year, Shares Outstanding stood at $119.0 million in 2021, then fell by 6.72% to $111.0 million in 2022, then changed by 0.0% to $111.0 million in 2023, then changed by 0.0% to $111.0 million in 2024, then soared by 45.95% to $162.0 million in 2025.
  • Business Quant data shows Shares Outstanding for DGX at $162.0 million in Q4 2025, $162.0 million in Q3 2025, and $112.0 million in Q2 2025.